Allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Research output: Contribution to journalArticlepeer-review


Colleges, School and Institutes

External organisations

  • University of Oxford
  • University of Washington


Allogeneic stem cell transplantation is an increasingly important treatment option in the management of adult acute myeloid leukemia (AML). The major causes of treatment failure remain disease relapse and treatment toxicity. In this review, Dr Vyas presents an overview of important recent data defining molecular factors associated with treatment failure in AML. He also identifies the emerging importance of leukemia stem cell biology in determining both response to therapy and relapse risk in AML. Dr Appelbaum discusses advances in the design and delivery of both myeloablative and reduced-intensity conditioning regimens, highlighting novel strategies with the potential to improve outcome. Dr Craddock discusses the development of both novel conditioning regimens and post-transplantation strategies aimed at reducing the risk of disease relapse.


Original languageEnglish
Pages (from-to)8-15
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Issue number1
Publication statusPublished - Jan 2015


  • Adult, Chromosome Aberrations, Disease Management, Drug Resistance, Neoplasm, Graft vs Leukemia Effect, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Myeloablative Agonists, Neoplastic Stem Cells, Recurrence, Survival Analysis, Transplantation Conditioning, Transplantation, Homologous, Treatment Failure, Journal Article, Review